GoCompare deploys fraud busting technology from Featurespace

GoCompare, one of the UK’s most established and popular comparison and switching websites, has partnered with Cambridge fraud detection specialist Featurespace to strengthen its front-end fraud prevention and detection abilities.

GoCompare is the only UK-based comparison website to use Featurespace’s ARIC™ Fraud Hub, which uses real-time machine learning developed out of Cambridge University to spot anomalies, block new fraud, and recognise genuine customers. 

This will build on GoCompare’s existing efforts to tackle quote manipulation, ghost broking, application fraud, and more. For insurers who partner with GoCompare, the suite of fraud detection and prevention tools available will enable customised, real-time risk management, reducing the burden on insurers’ own fraud teams.

Fleur Lewis, head of fraud at GoCompare, said: “We’re excited to be the only UK comparison website to be partnering with Featurespace. 

“Following an extensive evaluation of providers, they proved to be the only ones capable of enhancing our existing fraud prevention capabilities. We recognise that comparison websites act as the gatekeepers of data for many insurers and that we have an important role to play in the prevention of front-end fraud.

“Any online platform is a potentially inviting place to attempt fraud, and we believe we can support the industry in identifying this sort of behaviour by introducing detection and prevention measures at point-of-quote. 

“These capabilities enable insurers to assess the risk in real-time and either decline the business or price accurately to ensure all parties are suitably protected.

“Our ambition is to provide insurers with only quality, genuine customers, thereby reducing their operational/legal costs and losses, so that they can continue to provide our users with excellent cover that represents value for money.”

Martina King, CEO of Featurespace, added: “The intense deliberation in seeking a fraud and risk technology provider reflects GoCompare’s commitment to safeguarding their customers and their business. We are honoured to have been selected.”  

GoCompare’s anti-fraud project will evolve over the coming 12 months, with the introduction of third-party data enrichment feeds and new business intelligence partnerships.  

• PHOTOGRAPH SHOWS: Martina King

GeoSpock Collaborates With GeoWorks On Large Scale Geospatial Data Processing Innovation

GeoSpock Collaborates With GeoWorks On Large Scale Geospatial Data Processing Innovation 

Data visualisation company announces participation in the Singapore Land Authority’s geospatial technology initiative

 Cambridge, UK, 13 December: GeoSpock® – the extreme-scale, data integration company that provides analytics, builds insight, and enables predictions across space and time – today announced a collaboration with the Singapore Land Authority (SLA) to drive large scale geospatial data processing and analytics. The introduction of GeoSpock’s data processing engine will enable location intelligence and rapid visualisation, supporting GeoWorks in the drive to promote business growth and innovation across industries.  GeoWorks was set up by the SLA as an industry centre to foster a vibrant geospatial ecosystem by connecting geospatial businesses, entrepreneurs as well as users and support them with the resources and expertise to catalyse geospatial innovation and solutions.

For a start, GeoSpock will utilise the SLA’s OneMap datasets for geospatial-temporal visualisation on GeoSpock’s platform to accelerate business intelligence and insights. The collaboration will explore the use of GeoSpock’s technology as a ‘data ocean’ for multiple disparate geo-temporal datasets to enable efficient cost optimisation of extreme-scale datasets, as well as the dynamic visual and programmatic analytical access for onward downstream use. The partnership will also utilise GeoSpock’s technology to provide lightweight and fast 3D data processing; this vision includes the exploration and design of a centralised, accessible Smart City Operating System (OS).

Richard Baker, CEO at GeoSpock, comments: “GeoSpock is delighted to join GeoWorks and collaborate with the Singapore Land Authority (SLA) team. The development of data science and geospatial analytics at scale for use across Singapore is critical to support the country as it innovates for the future, and we are committed to their vision to advance spatial big data management and analytics, data science capabilities, and machine learning technologies.”

SLA Geospatial and Data Director and Chief Data Officer Ng Siau Yong said: “Geospatial data and analytics empower both governments and businesses for effective and efficient decision-making, and the creation of applications that benefit the community. We are pleased to welcome GeoSpock to the GeoWorks community and look forward to sharing their expertise to facilitate the co-innovation of geospatial solutions.” 

GeoSpock provides a unique location intelligence platform that enables companies to access real-time data evaluation. Petabyte-level processing empowers decision makers to employ these insights to predict future scenarios. The data visualisation company is fast establishing itself as the de facto processing engine at the heart of next-generation smart infrastructure – including smart cities and the Internet of Everything (IoE). The company is also powering future mobility applications, such as the management of autonomous vehicle fleets, by working with businesses across the automotive, telecoms, mobility, marine, media, and retail sectors.

UK-based techspert.io secures €1.1 million for its AI-powered expert finder

Company of the month: Ieso Digital Health

Each month we profile an innovative, growing company from across the Greater South East of England. Ieso Digital Health is a world leading digital health company in Cambridge, specialising in internet enabled evidence-based psychological therapies. We spoke with Rob Brougham, UK Managing Director, about their exciting research in mental health and their aim to speed up patients’ recovery rates.

What do Ieso Digital Health do?

Iseo is a digital health company, however, we put the emphasis very firmly on the health part of our name. We are a healthcare company first and foremost, and it just so happens that the way in which we deliver the care is using digital tools. We are working in the mental health space and we provide high-quality, evidence-based, cognitive behavioural therapy. So, we are helping patients with depression, anxiety and other common mental health issues.

How does this work in practice?

In the UK, we work within the NHS Improving Access to Psychological Therapy (IAPT) programme, which has been running for about a decade, and it was created to bring cognitive behavioural therapy to as many people as possible across the country. It is a very data-rich part of the NHS, so they are recording outcomes to try and improve quality over time.

We are suppliers into that, so our customers are the CCGs and the NHS mental health trusts. We are also now starting to work in the US with some of the big healthcare companies there.

How big is the company?

We have 500 therapists in our network and they provide therapy to patients which is very similar to face to face therapy, but in an online manner and it is through typing as opposed to physically seeing each other. Typically, they meet once a week, for an hour, and it is the same therapist each time. The therapists and the patients can be wherever is convenient for them, such as from their home or in a meeting room at work.

We’re treating NHS patients who would normally only be given the option of Monday to Friday. When you give them a choice, over two thirds of them choose to have therapy at a different time and it’s a time when they can fit therapy around their life and not the other way around.

How did the company come about?

It was founded by two clinical psychologists who were working within the NHS about 15 years ago. They were delivering cognitive behavioural therapy (CBT) to patients within the NHS, and they could see how beneficial it was. They felt that they’d be able to use the internet to make it easier and more convenient for patients to access CBT. So, they had the original vision and it turned out they were right – the core of the service they created is still the foundations of what we deliver today. And we’ve now built on that and we treat many thousands of NHS patients across the country every single year.

What impact would you say that your technologies have had?

Making it convenient and easy for patients to access therapy has been a really important thing that we’ve brought to the party. Because we have 500 therapies and because of the way in which we are organised, we don’t have a wait list at all. One thing that is very well researched is that the longer a patient waits for therapy, the less likely they are to recover.

We have also been able to support clinical outcomes because of the way we deliver therapy and for the first time ever, we can see exactly what happens in every therapy session and we’ve used that to create an effective supervision and training environment.

We are now applying sophisticated data science to begin to understand, in detail, what works best for patients, and to create artificial intelligence-based tools that can help our therapists to provide even better results going forward.

Can you tell us about your use of AI in your technologies – and what do you think the future looks like for AI and healthcare?

We have developed a suite of tools which are focused on what we term ‘therapist augmentation’. These are therapist facing tools that help them to do a better job to support more patients and then ultimately get more patients better more quickly.

One example is our dropout predictor. Dropout is common in CBT, because the patients may not feel ready or it is inconvenient for them. Based on the initial presentation of the patient, what they first type and what they first put into the system, our AI tool can predict which patients are at a higher dropout risk and can advise the therapist accordingly. So that therapist can then adjust his or her approach, such as by booking in the next few appointments at the end of the first session

CBT is very much evidence-based and there is a lot of research over many years showing what works and what doesn’t work. We’re working on a tool which can provide therapy insights; it can tag the active ingredients of a therapy session and show that back to the therapist so they can see what they could be doing better to support that patient. The therapist  can then make sure they add those positive active ingredients back into the session, in real time.

Which organisations do you work with?

Alongside our work within the NHS, we’re very much a clinical and a scientifically-led company that is backed up by evidence. We are very active in terms of doing research in collaboration with universities, such as University College London, the University of East Anglia and Queen Mary University of London and we are expecting to do some active research projects with Cambridge University.

How have you gone about funding your technologies?

We recently won an Innovate UK grant, but most of our funding has come from investors. Our early-stage angel investors from Cambridge Angels Network are still actively involved as investors in the business. As the company developed and as the evidence base grew stronger, the company was able to secure some venture capital funding with our biggest funding coming from IP Group and Draper Esprit.

Why did you choose to base your business in Cambridge?

We are situated in Cambridge because it is great in terms of attracting the talent that we need. We’ve invested very heavily in the technology and in the commercial aspects of the business and we found Cambridge to be the perfect place to find the right people with technical, commercial and other skills necessary in order to build the business. But, of course, we deliver therapy wherever and whenever patients need it.

What’s next on the horizon?

Firstly, we’re very excited about the therapy insights tagging tool that we’re developing. This is likely to evolve to help therapists to adhere to the evidence base, and we could begin to work out how we could personalise mental health care delivery.

We’ve also conducted research into depression which has always been one of the hardest conditions to treat with CBT, our data indicates that it isn’t just one condition but actually multiple sub conditions. These subtypes of depression respond differently to different therapy protocols, so we are looking to identify which of those protocols is best able to treat which subtype on depression and begin to drive up recovery rates.

The Innovate UK grant will be used to research into digital biomarkers, by gathering insights from patients’ smartphones sensors. Over time, we want to extend that to identify earlier, the onset of mental health issues, and help patients by treating them more effectively with more affordable treatments.

Audio Analytic start-up making a big noise in home technology

As a baby starts to cry, a soothing voice can be heard from the corner of the room. “Don’t worry, little one,” it says. “Daddy is on his way.” But there’s something missing. There’s no parent or babysitter to be seen, only an electronic smart speaker that a Cambridge-based company is training how to listen and respond to the world around it.

For eight years, Audio Analytic has been developing software that can identify background noises, from recordings of crying babies to barking dogs. It’s probably the only technology start-up that reserves a portion of its budget for smashing windows. According to Chris Mitchell, its founder and chief executive: “We were set up to give machines a sense of hearing.”

Speech recognition is an established area of artificial intelligence, with an increasing number of homes owning some form of listening device, from Amazon’s Alexa to Apple’s Siri. People are used to asking them for a weather update or a reminder about meetings in the calendar.

Audio Analytic wants to broaden the assistant’s horizons. “When we deal with all the sounds in the universe — babies crying, dogs barking, windows being broken — none are governed by language models. You need very different types of artificial intelligence to deal with these and it’s a very new field,” Dr Mitchell said.

When he founded the business in 2010, there were no companies working in sound recognition. He had completed his PhD in a related field at Anglia Ruskin University and had a choice. “It was either go and do something else, or form a company that did it.”

Audio Analytic raised $8.5 million from investors and has partnerships with large technology companies including Cisco, Intel and Hive, the “smart home” division of Centrica. It has 42 employees at two locations in Cambridge, plus a sales office in San Francisco.

Forming a company was not such a leap for Dr Mitchell, 38, who funded his PhD by running his own network consultancy business. Balancing entrepreneurship and studies wasn’t easy — professors don’t always appreciate their students running off to fix clients’ software — but it proved useful preparation.

Audio Analytic ventured first into the connected home market, with products including a light bulb that detects the sound of windows being smashed. It has worked on home security cameras and speakers and earlier this year announced a partnership with Bragi, the headphone maker, to embed listening software to alert pedestrians and cyclists to hazards such as an emergency vehicle. Integrating the software into self-driving cars and health devices that can listen out for a patient’s audible symptoms, such as coughs and sneezes, are next on the agenda.

The first step in the start-up’s journey involved deciding which sounds to index and analyse. Dr Mitchell can recall trying to list every noise that might be useful and marketable. “What I quickly ended up with was a list of sounds and the realisation that I didn’t really know how to value markets.”

Now Audio Analytic has licensed six common sounds to clients and has a further fifteen in development. All are recorded and analysed in a vast, soundproofed space that removes all environmental or background effects so that computers can learn the most basic form of a sound. Within this foam-decked room, all manner of sounds are recreated, from the smashing of windows — a rite of passage for new employees — to crying sessions with babies.

“When devices respond to these sounds, they suddenly take on less inanimate properties,” Dr Mitchell said. “They tend to [feel] more caring, more understanding . . . more of the things you want from modern consumer electronics.”

An Alexa speaker, after notifying parents that the baby is crying, can play Twinkle Twinkle Little Star. When a window breaks, it announces that it will “turn on lights, play the loud alarm, notify the owners and set the lasers to stun”. Cue a grin from Dr Mitchell. “We’ve got to have fun with Alexa.”

The company takes a “follow the money” approach to choosing noises, but pushing the boundaries of artificial intelligence is as important as commercial success. “Giving something a sense of hearing is valuable. We’ve got two ears for a reason.”

Silicon Fen’s bridge to the world of finance
The concentration of start-ups in Cambridge has given it the nickname Silicon Fen and Cambridge Ahead, the lobby group, calculates that its 3,000 technology businesses have a combined turnover of £4.1 billion and support nearly 20,000 jobs (Emma Yeomans writes).

The city’s technology heritage owes much to the close links between industry and its university. Arm Holdings, the computer and smartphone chip maker now owned by Softbank, of Japan, is probably the best-known success story.

Some famous players have a base there, too, including Amazon, while Apple confirmed rumours last year that it had a development office for its Siri artificial intelligence personal assistant software in the city.

Cambridge also has its own network of venture capitalists, including IQ Capital, Cambridge Angels and Rockspring, and these local investors were where Audio Analytic found its first funding.

Many of those who saw the AI software company’s potential had been entrepreneurs themselves, Chris Mitchell, its founder, said, adding that it is a positive thing for young companies. “You need people who know how to build early stage companies investing back into start-ups, because they invest under different criteria [to other financiers].” He may need patient investors as he insists that the bottom line isn’t everything — a distinction between the model of British start-ups and their American counterparts, which want to commercialise their products more quickly.

Cambridge Angels investing millions to fill funding void for global hopefuls

According to The UK Business Angels Association, which has a hub at The Bradfield Centre in Cambridge, business angels in the UK collectively invest an estimated £1.5 billion a year, which makes them the UK’s largest source of investment for startups and early-stage businesses seeking to grow.

To say that angels are helping fledgling businesses negotiate the valley of death is a gross understatement. It is hard to imagine where the startup community would be without their often divine interventions.

The Cambridge science & technology cluster has more than its fair share of seraphims, cherubims and archangels who have collectively wrapped their wings – and their wallets – around constant cohorts of hopefuls.

The Cambridge Angels group is one of the oldest such networks in the UK, having been founded in September 2001 by Robert Sansom and David Cleevely.

Robert was founding chair and David – plus John Yeomans – were subsequent high profile chairs. Peter Cowley took the role in 2016 and is also president of the European Business Angel Network. John Yeomans specialises in data businesses, notably in digital media and communications.

It is worth mentioning for context that among a great many technology achievements, Robert Sansom was also a board director of FORE. In 1999, when it employed over 2,000 people and had annual revenues of over $600 million, FORE was sold to Marconi (previously GEC plc) for $4.5 billion. Dr Sansom continued as Marconi’s chief technology officer until April 2000.

Since inception 17 years ago, Cambridge Angels have invested more than £75 million in over 80 different portfolio companies.

One recent exit was particularly spectacular as Oracle acquired John Snyder’s Grapeshot; other notable exits included 3Way Networks, AlertMe (bought by British Gas for £65m), Cambridge CMOS Sensors, Cronto, Oval Medical Technologies, Neul (acquired by Chinese giant Huawei) and Phonetic Arts, this latter acquired by Google.

Digging deeper into the portfolio, Cambridge Angels-founded companies include Abcam, a global life science tools provider; Raspberry Pi – creator of a world-leading micro computer; fabless semiconductor company CSR and other leading technology players such as Frontier, Alphamosaic (acquired by Broadcom for $120m in 2004) and Privitar.

Thanks to Robert Sansom and Peter Cowley we can reveal that the first pitch event held by Cambridge Angels was on October 1, 2001 and that there were 19 members initially with a further nine entrepreneurs waiting to join – in the wings presumably!

The first two pitches were Voxit and Force12, neither of whom have figured on our radar, but most of the other Cambridge Angels investments since most certainly have.

While the organisation is called Cambridge Angels the reach of the network, given the calibre and contacts of its entrepreneur membership, is international, which is a tremendous help to portfolio companies.
The group is highly collaborative, not just injecting crucial capital but also  actively mentoring entrepreneurial teams and their ideas to ensure they achieve returns and realise their full potential.

In terms of industry focus, Cambridge Angel members invest in a wide range of startup and scale-up businesses with a particular focus on technology, internet, software, hardware, digital healthcare and life sciences.

Membership of Cambridge Angels is by invitation only. Entrepreneurs who think they can add value to the network and businesses seeking financial support and associated mentorship should visit the website: cambridgeangels.com

• PHOTOGRAPH SHOWS: The Cambridge Angels Group co-founder David Cleevely

Novel Boost For Mobile Reliability

A new initiative from DC hybrid power systems manufacturer Controllis is set to help bring more reliable mobile coverage within reach of people in even the most remote areas.

The ‘Five 5s’ programme cuts the up-front and ongoing costs of providing reliable network power to mobile phone towers and offers peace of mind when it comes to maintenance – removing a lot of the barriers to deploying and operating mobile networks in rural communities in countries with little existing infrastructure.

“Our DC hybrid systems are already saving operators thousands of dollars per site per year while reducing downtime per site,” said Lee Johnson, head of sales and marketing at Controllis. “The Five 5s programme is designed to build on those benefits and address the issues operators have with hybrid systems – primarily cost of ownership, reliability and battery life.”

The Five 5s programme includes a unique 5-year battery-life guarantee, on top of 5 years of free remote monitoring, a full 5-year warranty on the hybrid power system, a 5-year leasing capability and the option of 5 nines of reliability – or 99.999% uptime.

“Our deployed customer base stretches from South America to Asia, Africa and Europe,” said Mr Johnson. “Millions of system running hours have given us the data and confidence to offer a solution that meets the commercial needs of both tower companies and mobile operators. In launching the Five 5s we are setting a new precedent in assuring the performance and operation of power networks.”

Tower companies typically spend hundreds of millions – and, in some cases, billions – of dollars buying and operating sites. The Controllis 5-year leasing option means they can avoid up-front costs on power systems and dramatically reduce ongoing costs – aligning their spend more closely with their operating models.

The remote monitoring element of the Five 5s programme includes a connectivity option via built-in data SIMs and access to the Controllis cloud-based remote management server. The visibility and control of remote sites provided by the monitoring dramatically reduces the number of site visits.

The Controllis range of DC generators and hybrid energy power solutions helps mobile operators and tower companies provide more reliable and cost-effective power networks – giving them competitive advantage through improved network access and a better user experience.

Eagle Genomics named Top 500 global deeptech startup

Knowledge discovery in life sciences company, Eagle Genomics, has been selected as part of Hello Tomorrow’s Top 500 deeptech startups worldwide.

More than 4,500 startups from 119 countries applied for the Hello Tomorrow Global Challenge – a science & technology startup competition designed specifically to address the needs of deep tech entrepreneurs across several different industries and technologies.

Thanks to the AI-powered knowledge discovery capabilities of its platform; the Automated Data Scientist, Eagle Genomics has been included in the AI & Data track of the Top 500, an accolade that recognises the company as one of the most promising in deeptech to date.

Eagle Genomics’ knowledge discovery platform, the Automated Data Scientist, utilizes AI and [Azure] cloud technology to transform data into actionable insights that drive scientific decision making. Enterprise customers are able to use the Automated Data Scientist, to exploit and navigate complex life sciences data to assess a product’s viability for retail / consumption by assessing, for example, its impact on the complex and unique human microbiome. The insight gained from the platform enables quick assessment of a products potential, accelerates market entry and mitigates early risk.

CEO of Eagle Genomics, Anthony Finbow, commented: “We are delighted to have been chosen from over 4,500 companies as one of the most promising deeptech startups. Our platform is applying context-based machine learning and AI to life sciences data enabling our customers to address some of the grand challenges of our age. This recognition from Hello Tomorrow only supports our mission to bring a step change in knowledge discovery in the health, food, personal care and agritech industries, enabling the digital reinvention of life sciences R&D.”

As finalists of the Top 500 deeptech startup challenge, Eagle Genomics will also attend the Hello Tomorrow Global Summit in Paris in March 2019.

GeoSpock Wins Liverpool Mayor’s ‘Smart Cities Realized’ Transport Challenge

GeoSpock Wins Liverpool Mayor’s ‘Smart Cities Realized’ Transport Challenge

Data visualization company awarded proof-of-concept project for Smart Transport Liverpool

Cambridge, UK, 23 October 2018: GeoSpock® – the extreme-scale, data integration company that provides analytics, builds insight, and enables predictions across space and time – today announced that it has secured the Smart Transport Award as part of the Liverpool Major’s Challenges for Smart Cities Realized.

Harnessing geospatial data enables cities to work smarter, GeoSpock’s solution proposes improvements to the mobility of Liverpool’s citizens, while also significantly reducing the city’s environmental footprint. The platform allows the input of historical and current statistics, as well as the subsequent tracking and analysis of these disparate datasets. Meeting the Transport Challenge’s sustainability criteria, GeoSpock’s solution will deliver tangible results to the identified issues and provide additional opportunities beyond the scope of the project. The prize for the most innovative submission is a proof-of-concept project for Smart Transport Liverpool and formal partnership with the city council, which GeoSpock will commence immediately.

The event was just one component of The International Business Festival, which saw the coming together of a number of global smart cities to share ideas, review technologies, and provide significant opportunities for the future in a market that is predicted to top over $2.4 trillion in 2025. Ideas were presented to a panel of experts, including Deputy Mayor of Liverpool Ann O’Byrne, Dr Jonathan Reichental, Cllr James Noakes, Professor Paul Morrissey, and Carl Piva. GeoSpock was awarded its winning status after delivering a crucial understanding of local blockers and demonstrating an effective solution that can be applied to the real world.

The data visualization company is fast establishing itself as the de facto processing engine at the heart of next-generation smart infrastructure – including smart cities and the Internet of Everything (IoE). The company is also powering future mobility applications, such as the management of autonomous vehicle fleets, by working with businesses across the automotive, telecoms, mobility, media, and retail sectors.

Richard Baker, CEO at GeoSpock, comments: “We are delighted to win the Smart Cities Realized, Smart Transport Challenge. Location Intelligence as a Service is fast becoming an important part of smart city development and this award is testament to the GeoSpock team’s innovation. We are looking forward to developing our relationship with Liverpool City Council and helping their smart city vision become a reality.”

Kate Hilyard joins Healx to drive the integration of AI with drug discovery for rare diseases

A senior pharma executive, with extensive drug discovery expertise, Kate’s appointment underlines Healx’s mission to combine deep pharmacological expertise with Artificial Intelligence (AI) and active patient engagement to give sufferers of rare disease a better quality of life.

At Healx, Kate will be lead strategy implementation to drive business growth enabling Healx to deliver rare disease treatments at scale through AI and cutting-edge technologies. Her industry experience adds to that of co-founder Dr David Brown, the inventor of Viagra and ex-Global Head of Drug Discovery at Roche, and the Healx drug discovery team. The Company’s massively parallel approach to drug discovery combines its unique AI technologies with one of the largest collections of insights from rare disease patient groups.

Welcoming Kate to the Company, Tim Guilliams, Healx’s co-founder and CEO said: “Kate brings a wealth of experience to Healx and her appointment is a real coup. Having started Healx with an artificial intelligence and patient care focus, Kate’s appointment broadens our senior expertise with further deep rare disease research knowhow and will be core to our goal of transforming the lives of patients, using our AI to find treatments based on existing drugs. Kate will help shape the next company milestones as we grow our world-class talent and demonstrate our ambition to transform the lives of rare disease patients.”

Kate’s track record of scientific and business leadership includes over 25 years’ drug discovery experience in the pharma and biotech sector, with a decade finding new treatments for rare diseases.  She joins from Charles River where she was Corporate Vice President Discovery, leading and integrating multiple sites in the UK, EU and US working with a global client base.  Previously she has held senior leadership roles at BioFocus DPI Ltd (which was acquired by Charles River) and Cambridge Antibody Technology (now part of MedImmune), having commenced her industry career at Roche. She gained her PhD in molecular immunology from Oxford University and her early academic career includes postdoctoral research in human biology at Oxford and Harvard Universities.

Commenting on her appointment, Kate Hilyard, COO, Healx said: “The unmet medical need for patients with rare diseases cannot be met using the traditional drug discovery and development approach. A radical shift away from blockbuster drugs towards more personalised treatments and patient-centric approaches is required. Using AI to discover new therapies has already been shown to be transformative in terms of time and money spent on clinical trials and Healx is at the forefront of changing drug discovery using AI. It is exciting to be joining the ambitious Healx team at this pivotal time, to use my extensive experience of transforming drug discovery organisations to make a difference to rare disease patient lives.”

In July, Healx announced that it had raised £10 million in a Series A financing which will be used to more than double Healx’s diverse and multi-disciplinary team of software engineers, data scientists, pharmacologists and drug development experts and to expand its world class artificial intelligence and machine learning technologies. Its Healnet AI platform facilitates highly parallelized, automated, large scale drug discovery that drastically reduces time and cost to discovery compared to traditional processes and can cut medicine development time by up to 80%.

PervasID receives £1.6 million investment to progress RFID technology

PervasID has completed a Series A investment and received an Innovate UK grant to progress RFID technology developed at the University of Cambridge.

PervasID, an award-winning RFID (Radio Frequency Identification) technology provider, today announces that it has secured £1.6 million in Series A funding. The technology, which was pioneered at the University of Cambridge and achieves more than 99 percent tag detection, was also awarded £240,000 from Innovate UK, the UK’s innovation agency.

Cambridge Enterprise, the University’s commercialisation arm, has backed the technology, along with Parkwalk, Cambridge Innovation Capital and Martlet, the investment arm of the Marshall of Cambridge Group. PervasID will use the additional funds to grow its delivery team, expand its reach into the healthcare, retail and industrial sectors, and provide essential innovation for its products.

PervasID was founded in 2011 by Dr Sabesan Sithamparanathan, Dr Michael Crisp, Professor Ian White and Professor Richard Penty. The company, which is based at St John’s Innovation Centre, Cambridge, has developed a passive RFID technology that enables highly reliable reading of standard passive RFID tags.

Since receiving its first round of funding in 2016, PervasID has expanded its product offering and now has over 30 corporate customers who use the patented technology, which achieves almost 100 per cent detection. The technology provides location information in a wide area read zone and can scale up to service larger areas, such as shops and warehouses, in order to provide better stock visibility. It can also integrate with existing alarm systems to alert of theft, making it, in the words of one of PervasID’s major tier one retail customers, “arguably the best and the only solution up to the challenge facing modern retailing.”

Dr Sabesan Sithamparanathan, co-founder and CEO comments, “We are very pleased to have successfully closed this funding round which will help us innovate and develop our product further. The investment we have received from local investors is a particularly proud moment for us as they are backing technology that has been pioneered at the University of Cambridge. This highlights the importance of supporting research and development at these institutions.”

He continues, “Along with the Innovate UK grant, this funding will help us expand our team and therefore our expertise, which will allow us to continue to innovate our product offering in the future.”

Dr Elaine Loukes, Investment Director at Cambridge Enterprise, comments: “We are delighted to continue to support the company. With its expanded range of products and market applications, many customers are recognising the benefits of the PervasID technology.”

Moray Wright, CEO, Parkwalk adds, “Parkwalk is delighted to have invested in this globally-leading RFID technology that will enable customers around the world to monitor their assets in real time. The fundamental research behind the technology is ground breaking and opens new opportunities for passive RFID in a range of markets.”

Andrew Williamson, Investment Director at Cambridge Innovation Capital, comments “PervasID’s high accuracy RFID sensor technology addresses an unmet need in the retail, healthcare and industrial sectors. We are excited by advances to PervasID’s technology and the growth of their team since CIC made our initial investment in 2016.”

Peter Cowley, Investment Director at Martlet, the investment arm of Marshall of Cambridge Group and very active technology angel investor comments, “We’re pleased to be backing another innovative Cambridge technology start-up that offers a technical advantage over existing RFID tracking solutions, providing much better performance at lower cost. With my background in developing and selling RFID solutions across multiple sectors for over two decades, I will be able to support the company in delivering value to customers and achieving its growth plans.”   

SyndicateRoom CEO scoops CEO Excellence Award

Goncalo Vasconcelos, CEO of SyndicateRoom, has been awarded a Global CEO Excellence Award for 'Best Online Investments CEO 2018'.

Now in its second year, the Global CEO Excellence Awards has returned to recognise the outstanding achievements made by leading CEOs from across the world. The awards reveal the CEOs responsible for driving change while successfully managing the day-to-day operations within an organisation, and are more than just role models for their employees and can operate as motivators and innovators, with the vision and drive to take an enterprise to the next level.

SyndicateRoom has also been nominated for a Growth Investor Award with the Intelligent Partnership, for Best Investment Platform. After an intense judging process, the six finalists for the category were recently announced. Winners will be confirmed over the next few weeks, and celebrated at an awards ceremony this November.

SyndicateRoom are Alumni of ideaSpace West.

SyndicateRoom is an online equity crowdfunding platform that allows its members to co-invest in high-growth companies with experienced investors including some of the most prominent Business Angels in the UK.

Repositive strengthens senior management team for new growth phase

Repositive, a Cambridge UK technology startup bidding to help accelerate cancer drug discovery, has hired three senior executives to ready the business for its next phase of growth.

Established in 2014 as a social enterprise, Repositive has grown its headcount by 50 per cent in the last 12 months and now numbers 38 people. The company has created a secure platform that helps increase discovery, access to and sharing of genomic research data for the benefit of patients.
 
Repositive has created two products based on its platform through which communities of researchers and data providers can connect and share previously hard to access data and models, to support research studies.

The three new senior hires are Ave Wrigley as chief technology officer; Robert Thong as chief business officer; and Julian Coe, chief finance and operating officer.

Wrigley, has over 20 years’ experience running technology departments across a wide variety of disciplines – including ecommerce and digital marketing, data-driven marketing insights and multimedia content management – and will help Repositive focus on scalable delivery and maximising the benefits of the platforms for researchers and data providers.

Robert Thong brings almost 30 years of experience in leadership and commercial roles in B2B enterprises in the life sciences sector. Thong is a recognised authority on the biopharma R & D externalisation trend, a published author on biopharma R & D partnerships and also a guest lecturer on R & D alliances at institutions including the University of Cambridge and University College London. 

Julian Coe is an experienced finance director who has previously supported large health companies – such as LGC Genomics and Ieso Digital Health – with creating business plans, developing finance models and securing funding.

Coe said: “Repositive has incredible potential and I am determined to use my experience to help the company raise the funding it needs and to scale its operations to execute its growth plan. 

“Precision medicine is the future but its development requires biomedical researchers to have immediate access to a much greater volume of more pertinent genomic data. Repositive is making waves in the research world by providing this advanced search capability.

“We now have an incredibly strong team and we are confident that, in the next six months, we will be the world’s single largest source of translational cancer models for researchers.”

Repositive’s first data-sharing product, Discover, was launched in 2016 to enable researchers globally to locate any human genomic data that is already publicly available but is often not, for a number of reasons, easily located or accessible.

Discover now indexes over one million datasets from more than 50 data sources, and is forming the basis of Repositive’s contribution to the NIH Data Commons initiative.

Responding to demand from biopharma and biotech companies, Repositive has also developed a second product based on its secure platform, which is poised to become the world’s largest marketplace and community for translational cancer models. 

Repositive’s Cancer Models provides commercial oncology researchers with a holistic, searchable, comparable view of existing cancer models across the globe, whilst providing Contract Research Organisations – providers of cancer models – with a tool to market, showcase and manage their model inventory.

• PHOTOGRAPH SHOWS: Julian Coe

DefiniGEN strengthens Board with appointment of Professor Sir John Savill

DefiniGEN, the world leader in human iPSC differentiation and disease modelling, announces the appointment of Professor Sir John Savill as a Non-Executive Director of the Board.

Sir John will bring his expertise in translational science to DefiniGEN enabling the company to accelerate the development of new products and services which can improve the efficiency and economics of drug development.

Sir John Savill was previously the Chief Executive of the Medical Research Council (MRC) in the UK. Within this role he was responsible to UK Parliament for expenditure of approximately £800 million per year as MRC’s Accounting Officer. Alongside the MRC role, Savill was also Vice-Principal and Head of the College of Medicine at the University of Edinburgh. As a renowned expert in research and innovation, Sir John will aid DefiniGEN in further developing its partnerships with the pharmaceutical and biomedical communities.

Dr Marcus Yeo, Chief Executive Officer, commented: “I am delighted to welcome John to the DefiniGEN board. With his extensive experience as a highly-regarded clinician and scientist I am confident that John will prove to be highly valuable as DefiniGEN continues to grow internationally in key markets.”

Sir John Savill stated: “DefiniGEN is one of the UK’s most innovative translational science companies providing valuable tools for biomedical research. I’m delighted to join the board at this important stage in the company’s development.”

DefiniGEN provides human liver cells for preclinical drug development and disease modelling applications using human Induced Pluripotent Stem Cell hIPSC technology.

Featurespace joins the 'Sunday Times' Hiscox Tech Track 100

Featurespace has been ranked among the Sunday Times Hiscox Tech Track 100 league table, which ranks Britain’s private technology, media and telecoms companies with the fastest-growing sales.

The list, which was published in the Sunday Times yesterday (Sunday 9 September), ranks Featurespace as one of the fastest growing companies in the UK.  

Featurespace, which has been ranked 85 in the list, is the World leading provider of Adaptive Behavioral Analytics software for fraud and risk management. Their innovative application of machine learning technology provides a holistic solution to tackle new and known fraud attacks and is now protecting customer transactions for some of the largest banks, payment processors and companies across the world. 

The 2018 Tech Track 100 companies overall achieved average sales growth over three years of 101% a year to reach a combined total of £3.3bn. They employ 19,300 staff, having added 14,000 employees to their combined workforce over the period.

Featurespace is one of just five companies headquartered in Cambridgeshire (compared to six last year) to make the list. Between them, they have grown their sales by an average of 105% a year over three years to a total of £138m, and together they now employ over 1,000 people.

This year Featurespace aims to increase it's workforce to meet rising customer demand, with more than 100 new positions in London and Cambridge UK, and Atlanta GA - the home of it's US headquarters which opened in late 2017. 

Featurespace's fraud prevention software has won a number of exciting awards and nominations over the last 12 months, including The Queen's Award for Enterprise Innovation, The Women in IT Excellence Awards, FS Tech Awards - Anti-fraud Solution of the Year and a Gold Stevie at the American Business Awards. The company has also been ranked in the Deloitte Fast 50 two years running, as well as the FT100, Future Fifty, FinTech50 and European Business Awards 'Ones to Watch'.

To read more information, click here.

Featurespace™ is the world-leader in Adaptive Behavioural Analytics and creator of the ARIC™ platform, a machine learning software system developed out of the University of Cambridge. 

Headquartered in Cambridge, UK, and Atlanta, US with additional offices in London, UK, and New York, US. Featurespace has deployed ARIC to organisations that have services or products deployed in over 180 countries.

Arecor secures £6m investment for clinical development of its diabetes portfolio

Arecor Ltd, the UK-based leader in developing superior biopharmaceuticals through the application of an innovative formulation technology platform, today announces that it has secured £6 million of investment from new and existing investors for the clinical development of the Company’s speciality pharma portfolio of proprietary diabetes products.

Investment will accelerate the delivery of significantly improved therapeutic treatments and quality of life for people living with diabetes

This £6 million equity investment into Arecor was led by leading UK institutional investors, Calculus Capital, Downing Ventures, and Albion Capital with significant participation from Arecor’s existing investors. BioScience Managers Limited, the international healthcare investment firm, advised Downing Ventures.

Arecor’s next-generation diabetes product pipeline represents exciting new progress in the field of diabetes that will enable important new treatment regimens and offer greater control of blood glucose to diabetes patients, which is key to improving outcomes and quality of life. 

This pipeline includes:-

• Proprietary formulations of insulin analogues that are ultra-rapid acting and more closely match a healthy body’s physiological response to blood glucose, leading to better blood glucose (sugar) control - currently a significant challenge

• Highly concentrated rapid acting insulin optimised for the next generation of body-worn miniaturised delivery devices, including the artificial pancreas

• Stable aqueous ready to use glucagon used in an emergency to treat severe hypoglycaemia and enabling future use in bi-hormonal artificial pancreas systems

These programmes will be progressed through development to demonstrate improved product profiles and health outcomes in human clinical trials.  In addition to these clinical programmes, the investment will allow Arecor to progress its pre-clinical pipeline of diabetes combination products, as well as a range of additional superior biotherapeutics addressing critical unmet needs in key disease areas.

The management of diabetes is one of the major global health challenges.  Indeed, the International Diabetes Federation (“IDF”) estimates that there are nearly half a billion (425 million) people currently living with diabetes around the world* and the IDF further estimates that if the global direct and indirect healthcare costs from diabetes are included, the economic impact of diabetes exceeds $1trillion**.

The improved products, therapeutic pathways and personalised control that Arecor’s products can enable, will make a significant contribution to addressing this challenge.   Arecor will be taking its product portfolio into clinical development itself, however, the Company will ultimately look to partner with specialist diabetes companies for late stage clinical studies and global market access.

The Company, which was originally based on unique protein chemistry technology and insights spun out from Unilever, has refined and developed these into the ArestatTM formulation technology platform. This platform has been used extensively to improve the solution properties of numerous protein, anti-body, vaccine and peptide formulations both in collaboration with pharmaceutical partners, as well as for Arecor’s own pipeline.  Arecor has established a proven track record in applying this technology platform to deliver superior biopharmaceutical product profiles across a broad range of therapeutic areas.

Dr Sarah Howell, Chief Executive Officer at Arecor, commented: “We are delighted to have secured the investment that we need to progress our lead diabetes programmes through the key stages of clinical development.  With diabetes reaching epidemic proportions worldwide and with close to half a billion people living with the condition today, the opportunity of advancing our diabetes products into human clinical trials and their potential to significantly improve the treatment of this debilitating disease, represents a very exciting and ground-breaking proposition."

Alexander Crawford, Investment Director, Calculus Capital, added: “Arecor is applying its unique and highly regarded reformulation technology which will help transform the growing diabetes market. As lead investor, we believe this is an exciting new phase from Arecor in the development of their technology and strong growth potential.”

Dr Christoph Ruedig, Partner, Albion Capital, said: “We have followed Arecor for some time and are excited by the societal value of its fast onset, short duration action insulin. Its technology is highly differentiated and the Company is leading the sector in the area of stabilising liquid formulations for injectable drugs. We look forward to working with the strong leadership team to bring this extraordinary proposition to fruition and in doing so, aid many diabetic patients across the UK and beyond.”

Richard Lewis, Investment Director, Downing Ventures, concluded: “As an investment opportunity, Arecor combines a solid and high margin technology business alongside a proprietary product offering that fulfils major unmet medical need.  As a result, we believe that the diabetes pipeline should successfully attract quality international commercial partners. “

*  International Diabetes Federation. IDF Diabetes Atlas, 8th edition. International Diabetes Federation, 2017. Available at: http://www.diabetesatlas.org/

** Bommer C., Heesemann E., Sagalova V., et al. The global economic burden of diabetes in adults aged 20-79 years: a cost-of-illness study. Lancet Diabetes Endocrinol 2017; 5: 423-30.

About ArestatTM

Arecor has significant experience and a proven track record in applying the ArestatTM formulation technology platform to deliver superior biopharmaceutical product profiles across a broad range of proteins, peptides and vaccines.

About Arecor’s Patent Portfolio

Arecor’s technology is protected by 21 patent families, including 23 granted patents.  Arecor has been exploiting its technology in partnerships with pharmaceutical companies, successfully developing superior product profiles, including stable high-concentration antibodies with low viscosity, reformulations of lyophilised or freeze-dried products into stable liquids or stable vaccines that can be used outside the cold chain.

Undo appoints Barry Morris as CEO to lead growth phase

Undo, a pioneer in the development of new software execution record and replay technology, has announced the appointment of Barry Morris as its new CEO with immediate effect.

Morris will take over the role from co-founder DrGreg Law, who has to date been performing a dual CEO/CTO role. Law will now dedicate his time and focus to operating as Undo’s CTO, developing Undo’s technical capabilities in line with evolving customer demand.

Morris has swapped one Cambridge for another, moving from Cambridge, Massachusetts based NuoDB, to operate out of Undo’s Cambridge UK headquarters. A serial entrepreneur, Morris founded NuoDB in 2008 and most recently served as its Executive Chairman.

With over 25 years’ experience working in enterprise software and database systems, he is a prodigious company builder, scaling start-ups and publicly held companies alike. Morris, who was CEO of distributed service-oriented architecture (SOA) specialists IONA Technologies between 2000 and 2003, built the company up to $180m in revenues and a $2bn valuation.

Law commented, “We have achieved our early stage goals. With the industry-changing technology we have built, the customers we have signed up and the funding we have secured, it is time to move to the next stage of the plan, with an A-player to lead the company in its high-growth phase.

“Despite a really strong short list of candidates, the result of a worldwide executive search, we were unanimous in our agreement about who the right person to lead the company should be, and that’s Barry.”

Morris added, “Greg and the team at Undo have built incredible foundations for the company, with technology that was thought by many to be an impossibility, and an enviable customer list including IBM, SAP and Micro Focus. My focus will be on the next evolution of the company, as we strengthen our positioning in strategically important markets like the US and Europe.”

“There is a substantial opportunity for Undo right now.  All businesses are becoming highly dependent on software reliability, and Undo uniquely delivers reliability solutions across the software lifecycle. The industry wave of investment in continuous integration and deployment (CI/CD) is part of a drive for software quality, but the absence of a modern software reliability platform remains a pervasive challenge in these environments. Undo is perfectly and uniquely positioned to address this challenge.”

Undo has grown rapidly in recent years, growing headcount to 40, with a world-class engineering team in Cambridge and an experienced enterprise sales organisation in San Francisco. In July, the company announced that it had secured $14 million in series B funding, and has to date, raised over $20 million in venture funding from leading venture capitalists.

Law concluded, “We reached the size and complexity where it was impossible for one person to be both CEO and CTO. It’s a fantastic coup for the company to bring in someone with Barry’s international experience of putting innovative companies firmly on the map, raising finances, and building sustainable revenue streams.”

About Undo

Long thought of as the holy grail of software development, Undo has developed program execution record and replay technology that allows some of the world’s largest companies to quickly diagnose software failures which couldn’t previously be addressed. By introducing this record & replay technology as a new standard for software failure diagnosis and debugging, application vendors can safeguard their client relationships, limit reputational damage and protect their bottom-line.

Headquartered in Cambridge, UK, with an office in San Francisco, Undo is going from strength to strength. Founded as a bootstrapped start-up in 2005 by Greg Law and Julian Smith, the company received its first external capital investment in 2012, and has continued to attract the interest of angel investors and venture capitalists throughout its journey.

Undo’s products are used by thousands of software engineers to solve complex, real-world problems for leading technology companies, from Electronic Design Automation vendors to enterprise database software manufacturers. Today, customers include global players such as SAP, Cadence Design Systems, Mentor Graphics, and Micro Focus.

CCS welcomes Ontix to lead programme for Metnet 12Gbps unlicensed 60GHz mmWave backhaul

Cambridge Communication Systems (CCS) Limited is pleased to announce that telecoms infrastructure provider Ontix has joined CCS’s Lead Customer Programme for the introduction of the CCS Metnet 12Gbps unlicensed 60GHz mmWave access and backhaul solution.

Ontix will begin Proof of Concept activities in central London from Q4 this year.

Ontix plans to leverage the neutral host mesh network connected to fibre and provide high-performance backhaul services – powered by the Metnet 12Gbps 60GHz system – for small cells deployed on these assets by multiple mobile operators. 

Antony Tomlinson, CEO of Ontix, comments: “We embraced this opportunity to join CCS’s lead customer programme and work hand-in-hand with our trusted and chosen partner for the mesh network, as this will provide our team with the earliest access and closest collaboration on a key launch implementation of the Metnet 60GHz solution.  We plan to provide a neutral host transport network in central London delivering carrier-grade services to our customers, and our selection of CCS as our mesh network vendor is a primary factor in this bid-winning approach. ”

CCS CEO Steve Greaves adds: “We are delighted to welcome Ontix to the CCS lead customer programme for Metnet 60GHz as it begins work on this ambitious neutral host network in London.  Ontix will be working alongside CCS through the introductory phases of the Metnet 60GHz system, and will now benefit from priority access to the latest features and enhanced capabilities as the network expands.”

Metnet 60GHz is the latest advance in the CCS Metnet product line, and extends the award-winning Metnet self-organising mesh capability already proven at 26/28GHz into the unlicensed band at 60GHz.  Delivering carrier-grade services in an unlicensed band is a challenge perfectly suited to Metnet and the 3D SON™ capability of Metnet 60GHz, which manages interference across three dimensions – space, time and frequency.

The ultra-high capacity 12Gbps multipoint system is the first element in CCS’s new software-defined Mesh network architecture, with multiple Metnet 60GHz nodes operating as a centrally managed SDN-capable networking switch.

About CCS

CCS (Cambridge Communication Systems) is the creator of Metnet – the world’s only self-organising microwave backhaul for small cell, Next Generation Fixed Wireless Access (FWA), CCTV and fibre extension applications.

In major live deployments from Asia to North America, Metnet is powering networks to mmWave 5G performance – intuitively, scalably, flexibly and cost-effectively.

Delivering high capacity, ultra-low latency and ultra-fast deployment, Metnet is optimised for performance edge and multigigabit.

Metnet’s proven capability is trusted at the heart of some of the world’s most demanding and data-heavy networks, including a pre-5G network for Telefonica O2 in London, at the heart of the world’s largest financial centre.

With a unique self-organising mesh solution for realising 5G – and beyond – CCS’s innovation and vision is connecting the 5G world.

Eagle Genomics lands co-sell status as part of Microsoft for Startups Programme

Eagle Genomics joins a specialised group of high-growth startups, earning co-sell status as part of Microsoft’s new programme to collaborate on intensive joint sales and go-to-market initiatives.

The Cambridge-based genomics company graduated from the newly launched Microsoft ScaleUp programme that helps qualified tech companies accelerate enterprise sales by providing resources to prepare, market and sell with access to Microsoft’s Global Salesforce.

Eagle Genomics’ ground-breaking knowledge discovery platform the e[automateddatascientist] utilizes Artificial Intelligence (AI) to analyze complex genomic and microbiomic data at scale, delivering new insight and allowing enterprise brands to assess the viability, efficacy and safety of products.

The platform augments research to assess enterprise products through a better understanding of their impact on the microbiome. Insight gained enables rapid assessment of product potential, accelerates market entry and mitigates early risk. Eagle Genomics aims to serve trillion-dollar markets in food, consumer and health markets using the power and scalability of Microsoft Azure combined with AI Cognitive Services to enable the digital reinvention of life sciences R&D.

Charlotte Yarkoni, Microsoft’s Corporate VP, Growth and Ecosystems commented at the February 2018 launch of Microsoft for Startups, “We are committing $500 million over the next two years to offer joint sales engagements with startups, along with access to our technology…Microsoft is partnering with founders and investors to help propel their growth.”

Warwick Hill, MD of Microsoft for Startups, Western Europe added: “Eagle Genomics is set to transform the way global brands make scientific based decisions about the impact and power of their products. Eagle Genomics are the market leaders in delivering data driven insights for enterprises interacting with the most complex “virtual” organ - the microbiome.”

Eagle supplies quality outsourced bioinformatics solutions. We combine cloud computing and Next Generation Sequencing (NGS) expertise with a track record in building scalable, efficient genomics analysis workflows using both commercial and open source software. Our services have added value to R&D processes and reduced time to market at many global life sciences companies including big pharma, crop science, personal hygiene and animal health.

Featurespace team shortlisted in 6 categories ahead of Women in IT Excellence Awards 2018

Four members of the Featurespace team have been shortlisted for the Hero of the Year award, while CEO Martina King has received nominations for both Role Model of the Year and Woman of the Year.

The Women in IT Excellence Awards, led by Computing News, highlights the entrepreneurs, innovators, leaders and pioneers building the infrastructure of the future. Winners will be announced in November at a ceremony hosted by tech journalist Holly Brockwell, who is best known for founding the female-written, female-focused tech site Gadgette.

Representing Featurespace in the Hero of the Year Category are: 

• Lucy Griffin, Senior Data Scientist, Featurespace
• Megan Leoni, Graduate Data Scientist, Featurespace
• Milena Jonkisz, Customer Support Engineer, Featurespace
• Reka Burmeister, Senior Software Development Engineer in Test, Quality Assurance, Featurespace

In addition, CEO, Martina King, has been shortlisted for both Role Model of the Year and Woman of the Year awards. 

Commenting on the shortlist, Martina King, Featurespace CEO said, 'We're thrilled to have this recognition of the highly skilled team we have built at Featurespace. I am proud to have so many of the remarkable women on our team celebrated through this award, all of whom are experts who go above and beyond to ensure our customers recieve the best possible product and service.'

Want to know more? Lucy was recently interviewed for our Life at Featurespace blog - see what a career in Data Science at Featurespace looks like and read her advice for others considering this career path here.

Featurespace™ is the world-leader in Adaptive Behavioural Analytics and creator of the ARIC™ platform, a machine learning software system developed out of the University of Cambridge. 

Headquartered in Cambridge, UK, and Atlanta, US with additional offices in London, UK, and New York, US. Featurespace has deployed ARIC to organisations that have services or products deployed in over 180 countries.